|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | GlaxoSmithKline |
|---|---|
| Information provided by: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00501397 |
Purpose
The purpose of this research study is to evaluate the effect of several daily doses of ketoconazole (a medication used to treat fungal infections like athlete's foot) on a single dose of GSK189075 (an experimental diabetes drug), and also to evaluate the safety and tolerability of GSK189075 in healthy volunteers. The study will see whether ketoconazole causes GSK189075 to stay in your bloodstream for a longer period of time. It will also examine whether GSK189075 causes any changes in the amount of glucose you have in your urine.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Mellitus |
Drug: ketoconazole Drug: GSK189075 |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Pharmacokinetics/Dynamics Study |
| Official Title: | An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK189075 |
| Enrollment: | 22 |
| Study Start Date: | February 2007 |
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | GSK ( Study Director ) |
| Study ID Numbers: | KG2108197 |
| Study First Received: | July 13, 2007 |
| Last Updated: | October 9, 2008 |
| ClinicalTrials.gov Identifier: | NCT00501397 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
T2DM, drug interaction, ketoconazole, pharmacokinetics |
|
Anti-Infective Agents Metabolic Diseases Therapeutic Uses Antifungal Agents Diabetes Mellitus, Type 2 |
Diabetes Mellitus Endocrine System Diseases Ketoconazole Glucose Metabolism Disorders Pharmacologic Actions |